Three years ago, Eli Lilly was a steady, mid-sized drug company earning about 21 cents on every dollar of sales. Today it is earning closer to 32 cents on a base that has nearly doubled. That kind of improvement does not happen by accident, and it does not stop on its own. The question a single quarter can answer is narrow: did the machinery hold, or did something slip?
The gist of it
The math, meaning what the filed numbers actually show, is a company whose revenue and margins are both still expanding at the same time, which is rare. The mood, meaning what the market is currently paying, prices the stock well below Lilly’s own decade median valuation, which suggests the market has grown more cautious even as the business has grown stronger. Those two readings do not obviously belong together, and that gap is the story.
What the latest filing actually says
The 10-Q for the quarter ended June 30, 2026 lands inside a full-year 2025 that was already remarkable. The 10-K for fiscal year 2025 shows revenue of $65.2 billion, up 45% from the year before, with a net margin of nearly 32%. To feel the scale: in 2022, Lilly’s revenue was less than half that figure. By 2025, the number had more than doubled. The engine behind it is no secret. Zepbound, the obesity treatment, generated $13.5 billion in 2025 revenue alone, which illustrates how dramatically the company’s revenue base has expanded in recent years.
The Q2 2026 filing shows the build continuing. Margins are not compressing under the weight of growth, which is the usual trap when a company scales fast. Every dollar of new sales is, by our data, arriving with more profit attached than the dollar before it. That is the compounding part of the headline.
The pipeline: five new names and one acquisition
A drug company’s pipeline is its future revenue, the same way a builder’s land bank is its future homes. As of the Q2 2026 pipeline update filed August 5, Lilly added five candidates. Two entered early-stage testing in cardiometabolic health, one in neuroscience. More consequentially, two jumped directly into Phase 3, the final human-trial stage before a drug can seek approval: Muvalaplin for heart disease and Ixo-Vec for a form of age-related blindness called wet AMD. Phase 3 entries matter because they are close enough to approval that the market can start pricing them.
Then, on September 2, Lilly announced the acquisition of Merida Biosciences, adding MER511, a Phase 1 candidate targeting Graves’ disease and thyroid eye disease, two autoimmune conditions with few good treatments. The acquisition follows a string of earlier deals, including Orna Therapeutics and Ajax Therapeutics, that the Q2 filing notes as contributing to in-process R&D charges. Lilly is spending on options, not just harvesting what it already has.
A pipeline that is simultaneously adding early-stage bets and advancing late-stage candidates suggests management is not coasting on tirzepatide — a consideration investors in this space typically weigh when assessing duration of growth.
The drugs already approved: a widening map
Donanemab, sold as Kisunla for early Alzheimer’s disease, received Health Canada approval in May 2026, adding Canada to a market the FDA opened in mid-2024. A new Phase 2 study for Lewy Body Disease began recruiting shortly after, extending the franchise into a related condition. Orforglipron, an oral GLP-1 drug in the same class as tirzepatide but taken as a pill rather than an injection, completed its Phase 3 diabetes study earlier this year and is now enrolling adolescents. A pill that works like Zepbound could reach patients who will not self-inject, which is a meaningfully larger population.
Not everything went smoothly. The FDA declined to approve retifanlimab for lung cancer earlier this year, citing manufacturing issues rather than the drug’s trial results, which had actually met their target. That distinction matters: a manufacturing problem is fixable; a failed trial is not. The drug already holds European Commission approval for anal canal cancer, granted around the same time.
The valuation gap
At a recent price of $1,149, Lilly trades at about 53 times last year’s earnings, a multiple meaning the price tag per dollar of annual profit. That multiple sits below the stock’s own decade median, and the stock has retreated from its 52-week high — two data points that describe where the market’s current pricing stands relative to its own history.
The mood has cooled even as the math has improved. Whether that gap closes depends on whether the revenue growth rate holds anywhere near its recent pace, and that question will not be answered by one quarter.
Reading the numbers
- Revenue, FY2025: $65.2 billion. What it is: total sales across all drugs and markets for the year ended December 31, 2025. What it means here: Lilly’s revenue has more than doubled since 2020, a pace almost unheard of for a company this size. In everyday terms: if a local bakery did $100,000 in sales five years ago and now does $265,000, it has not just grown, it has been remade.
- Net margin, FY2025: 31.7%. What it is: the share of each sales dollar left after every cost, tax, and charge. What it means here: margins are rising alongside revenue, which means scale is helping rather than hurting. In everyday terms: a restaurant that keeps 32 cents of every dollar after rent, food, and wages is running an unusually tight kitchen.
- P/E ratio: ~53 times. What it is: the price a buyer pays today for each dollar of last year’s profit. What it means here: the market’s current pricing reflects a more cautious stance even though the earnings themselves are growing. In everyday terms: a house whose price-to-rent ratio has fallen while the rent itself has gone up.
- Zepbound revenue, FY2025: $13.5 billion. What it is: sales of the obesity drug in its first full commercial years. What it means here: a single drug now generates more revenue than the whole company did in its pre-GLP-1 era, illustrating how rapidly the business has been remade. The concentration is a risk and a strength simultaneously.
- Stock below 52-week high. What it is: the distance from the highest price reached in the past year to today’s price. What it means here: market sentiment has moved in a different direction from reported operating results over this period — a divergence the data in this piece describes but does not resolve.
For the standing yardsticks on Eli Lilly &: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Eli Lilly &.
Sources
- Lilly 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- Lilly 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Lilly 10-Q, quarter ended March 31, 2026 (SEC EDGAR)
- Lilly pipeline update, August 5, 2026
- Merida Biosciences acquisition announcement, September 2, 2026 (Motley Fool)
- Donanemab durability data and Health Canada approval (Neurology Live)
